12 Best Day Trading Stocks To Buy

Published on November 9, 2023 at 8:52 am by Usman Kabir in Hedge Funds, News

In this article, we discuss the 12 best day trading stocks to buy. If you want to read about some more day trading stocks, go directly to 5 Best Day Trading Stocks To Buy.

Over the past few years, the rise of a new generation of stock traders that like to engage in risky bets, coupled with the advent of stock trading mobile applications, has given increased popularity to an otherwise forgotten market phenomenon known as day trading. Day trading refers to buying and selling shares of risky companies multiple times over the course of the business day in order to exploit the volatility and gain maximum advantage from the asset. Although day trading was previously an institution-only domain, it has become more popular and profitable for retail traders of the present.

The two primary factors that investors should be wary of before they start day trading are liquidity and volatility of stocks. The former refers to how quickly an asset can be bought or sold, and the latter refers to the short-term fluctuation in the share price. Even if a stock is highly liquid, it does not necessarily mean that it is also highly volatile.

Day trading is not easy. Research suggests that investors that have a large difference between existing economic conditions personally and aspiration levels publicly hold riskier stocks in their portfolios. This explains why the younger generation of stock pickers is more inclined to engage in day trading than some of their older peers. However, there are also other reasons for this. According to a study by researchers at the University of California, 80% of day traders quit within the first two years. Amongst day traders, nearly 40% only trade for a month. After three years, only 13% remain active. By five years, this number falls down to seven.

This implies that the legendary stock traders of the present day were also day traders once. Day trading can be a fine entry-point into the stock market for the novice investor eager to learn more about the interconnection between fundamentals and news, and how they affect the share price of a company. Even though internet scams have forced many retail investors away from day trading, there are several day traders who are still able to make a successful and above-average living from engaging in this practice.

Our Methodology

The companies that have high liquidity, measured through trading volumes, and high volatility, measured through share price fluctuation in the past four weeks, were selected for the list. In order to provide readers with some context for their investment choices, the business fundamentals and analyst ratings for the stocks are also discussed. Data from around 900 elite hedge funds tracked by Insider Monkey in the second quarter of 2023 was used to identify the number of hedge funds that hold stakes in each firm.

A portfolio manager pouring over data monitoring stocks on a large wall of monitors.

Best Day Trading Stocks To Buy

12. Spectral AI, Inc. (NASDAQ:MDAI)

Number of Hedge Fund Holders: N/A

Average Trading Volume as of November 2: 2.23 Million

Share Price Gain in Past Month: 23%

Spectral AI, Inc. (NASDAQ:MDAI) operates as an artificial intelligence company. The firm aims to specialize in medical diagnostics for faster and accurate treatment decisions in wound care. The applications involve patients with burns and diabetic foot ulcers. Some of the products it markets include DeepView, a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention, as well as other AI tools.

In late October, Spectral AI, Inc. (NASDAQ:MDAI) announced that it expected the research and development revenue in 2024 to be around $28 million. For 2023, the firm forecast R&D revenue to be $17 million, down from a previous estimate of $25 million.

Among the hedge funds being tracked by Insider Monkey, Florida-based investment firm Meteora Capital is a leading shareholder in Spectral AI, Inc. (NASDAQ:MDAI) with 15,566 shares worth more than $164,000.

Unlike Amazon.com, Inc. (NASDAQ:AMZN), Microsoft Corporation (NASDAQ:MSFT), and Meta Platforms, Inc. (NASDAQ:FB), Spectral AI, Inc. (NASDAQ:MDAI) is one of the more volatile stocks on the market.

11. MMTec, Inc. (NASDAQ:MTC)

Number of Hedge Fund Holders: N/A

Average Trading Volume as of November 2: 2.8 Million

Share Price Gain in Past Month: 119%

MMTec, Inc. (NASDAQ:MTC) develops and deploys platforms that enable financial institutions to engage in securities market transactions and settlements worldwide. Some of the products include Securities Dealers Trading System, Private Fund Investment Management System, as well as Mobile Transaction Individual Client System and PC Client System. The business serves several high-value hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms, playing key roles in account management, risk management, and trading and execution.

MMTec, Inc. (NASDAQ:MTC) is based in Hong Kong and aims to provide brokers in the United States with a one-stop financial solution. The firm is set to hold the annual meeting of shareholders in the second week of November.

10. Outlook Therapeutics, Inc. (NASDAQ:OTLK)

Number of Hedge Fund Holders: 2

Average Trading Volume as of November 2: 10.5 Million

Share Price Gain in Past Month: 187%

Outlook Therapeutics, Inc. (NASDAQ:OTLK) is a biotech firm focusing on the development of monoclonal antibodies for various ophthalmic indications. On November 2, the company announced that it had reached an agreement with drug authorities in the United States on a clinical trial design for ONS-5010, an ophthalmic formulation of the drug bevacizumab. The agreement would allow for a resubmission of the Biologics License Application as early as the end of 2024, with potential approval around mid-2025.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) was founded in 2010 and is based in New Jersey. It has collaboration and license agreements with IPCA Laboratories Limited, Laboratorios Liomont, BioLexis, and Zhejiang Huahai Pharmaceutical, among others.

At the end of the second quarter of 2023, 2 hedge funds in the database of Insider Monkey held stakes worth $438,000 in Outlook Therapeutics, Inc. (NASDAQ:OTLK), compared to 4 in the previous quarter worth $218,000.

Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Millennium Management is a leading shareholder in Outlook Therapeutics, Inc. (NASDAQ:OTLK) with 143,733 shares worth more than $250,000.

9. Matinas BioPharma Holdings, Inc. (NYSE:MTNB)

Number of Hedge Fund Holders: 3

Average Trading Volume as of November 2: 17.5 Million

Share Price Gain in Past Month: 60%

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) is a clinical-stage biopharmaceutical company. It develops products using lipid nanocrystal (LNC) platform technology. The LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. One of the leading product candidates for the firm is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions.

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) stock has soared since mid-October after the firm announced positive results for a patient dosed with MAT2203, an oral formulation of the antifungal agent amphotericin B. The firm said it was looking to advance MAT2203 into Phase 3 testing as a treatment for invasive aspergillosis, a type of fungal infection.

Among the hedge funds being tracked by Insider Monkey, New York-based Millennium Management is a leading shareholder in Matinas BioPharma Holdings, Inc. (NYSE:MTNB) with 17,777 shares worth more than $6,000.

At the end of the second quarter of 2023, 3 hedge funds in the database of Insider Monkey held stakes worth $337,000 in Matinas BioPharma Holdings, Inc. (NYSE:MTNB), the same as in the previous quarter worth $237,000.

8. Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)

Number of Hedge Fund Holders: 3

Average Trading Volume as of November 2: 1.39 Million

Share Price Gain in Past Month: 259%

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) is a clinical stage biopharmaceutical company that develops antibiotics to treat bacterial infections. One of the leading product candidates for the firm is ibezapolstat, a mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. Another potential candidate is ACX-375C, an oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.

In mid-August, investment advisory HC Wainwright maintained a Buy rating on Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) stock and lowered the price target to $13 from $14, citing dilution for the target drop post the Q2 results.

At the end of the second quarter of 2023, 3 hedge funds in the database of Insider Monkey held stakes worth $3,212,000 in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), compared to 2 in the previous quarter worth $969,000.

Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Armistice Capital is a leading shareholder in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) with 1.1 million shares worth more than $3 million.

7. CEL-SCI Corporation (NYSE:CVM)

Number of Hedge Fund Holders: 3

Average Trading Volume as of November 2: 1.85 Million

Share Price Gain in Past Month: 43%

CEL-SCI Corporation (NYSE:CVM) is a clinical-stage biotechnology company that engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. One of the leading projects of the firm is Multikine, a Leukocyte Interleukin injection for patients who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. The firm is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer.

In late October, CEL-SCI Corporation (NYSE:CVM) announced Phase 3 data for its lead candidate, Multikine, saying that 73% of Multikine-treated patients versus 45% in a control group remained alive over five years in the trial, indicating 50% cut in mortality risk.

At the end of the second quarter of 2023, 3 hedge funds in the database of Insider Monkey held stakes worth $348,000 in CEL-SCI Corporation (NYSE:CVM), compared to 2 in the previous quarter worth $77,000.

Among the hedge funds being tracked by Insider Monkey, Florida-based investment firm Citadel Investment Group is a leading shareholder in CEL-SCI Corporation (NYSE:CVM) with 347,100 shares worth more than $836,000.

6. ImmunityBio, Inc. (NASDAQ:IBRX)

Number of Hedge Fund Holders: 4

Average Trading Volume as of November 2: 6.1 Million

Share Price Gain in Past Month: 112%

ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company that engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. The stock has gained in recent weeks after drug authorities in the United States accepted a resubmitted Biologics License Application for bladder cancer therapy Anktiva by the biotech firm. Patrick Soon-Shiong, the Global Chief Scientific and Medical Officer of the firm, said the firm would work closely with FDA to close the review in a timely manner.

ImmunityBio, Inc. (NASDAQ:BRX) has collaboration and licensing agreements with National Cancer Institute, Amyris, LadRx Corporation, GlobeImmune, Access to Advanced Health Institute, 3M Innovative Properties Company, and Sanford Health.

At the end of the second quarter of 2023, 4 hedge funds in the database of Insider Monkey held stakes worth $959,000 in ImmunityBio, Inc. (NASDAQ:IBRX), compared to 14 the preceding quarter worth $14 million.

In contrast to Amazon.com, Inc. (NASDAQ:AMZN), Microsoft Corporation (NASDAQ:MSFT), and Meta Platforms, Inc. (NASDAQ:FB), ImmunityBio, Inc. (NASDAQ:BRX) is one of the more volatile stocks on the market.

Click to continue reading and see 5 Best Day Trading Stocks To Buy.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

12 Best Day Trading Stocks To Buy

Published on November 9, 2023 at 8:52 am by Usman Kabir in Hedge Funds, News

Best Day Trading Stocks To Buy

12. Spectral AI, Inc. (NASDAQ:MDAI)

11. MMTec, Inc. (NASDAQ:MTC)

10. Outlook Therapeutics, Inc. (NASDAQ:OTLK)

9. Matinas BioPharma Holdings, Inc. (NYSE:MTNB)

8. Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP)

7. CEL-SCI Corporation (NYSE:CVM)

6. ImmunityBio, Inc. (NASDAQ:IBRX)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff